Gossamer Bio, Inc. - GOSS Company Short-Term Debt

Graphic logo of Gossamer Bio, Inc. (GOSS)

Gossamer Bio, Inc. (GOSS) focuses on developing treatments for pulmonary hypertension, with the success of seralutinib and the search for strategic partners serving as the primary growth drivers. Business stability relies on patent protection, although risks remain high due to dependence on a single molecule. The company aims to outperform competitors through innovative inhalers. The current metric stands at 0.00, which is clearly demonstrated by the company's historical share price action.

GOSS (Gossamer Bio Inc) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

Gossamer Bio Corp. - analytical breakdowns and key metrics (GOSS)

- price and consensus price forecast:
Price Chart Gossamer Bio|GOSS - Fair Value Consensus
- market capitalization data:
Market Value Gossamer Bio, Inc.|GOSS - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Gossamer Bio|GOSS - Book Capitalization|Market Cap to Net Assets Ratio gossamerbio.com|GOSS - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Gossamer Bio, Inc.|GOSS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Gossamer Bio, Inc.|GOSS - Company Total Debt|Debt to Book Capitalization Ratio Gossamer Bio, Inc.|GOSS - Company Long-Term Liabilities|Company Current Liabilities Gossamer Bio
Fundamental company valuation:Gossamer Bio - GOSS
Product sample of Gossamer Bio, Inc.

For the biotechnology sector, where Gossamer Bio, Inc. (GOSS) is developing a unique treatment system for pulmonary hypertension, liquidity control is a critical survival factor. Aggregate short-term liability data reflects the total sum of all loans maturing within one year. The trend of this metric demonstrates the company's ability to fund scientific research and development without the risk of default. A stable debt level confirms financial stability during the scaling of therapy. It is essential for investors to see a balance between the debt load and the pace of innovation development.

Competitor analysis

Company Short-Term Debt argenx (ARGX)|BNTX: Company Short-Term Loans and Borrowings|ABVX (Abivax) - Company Short-Term Debt|ADMA Corp (ADMA) - Company Current Liabilities|PTGX (Protagonist Therapeutics) - Company Short-Term Debts|Company Short-Term Debts immunovant.com (IMVT)|Kiniksa (KNSA) - Company Current Liabilities|Company Short-Term Loans and Borrowings Grifols SA (GRFS)|Company Short-Term Debts ADPT|Celldex Corp - Short-Term Debt Volume|AUPH: Company Short-Term Debt|BCRX: Company Current Liabilities|VERA (Vera Therapeutics) - Company Short-Term Debt|Company Current Liabilities Dianthus Therapeutics Inc|PHVS (Pharvaris Corp) - Company Current Liabilities|Company Short-Term Debts ABCL|Company Short-Term Debt Tourmaline Bio, Inc. TRML|Company Short-Term Indebtedness precigen.com (PGEN)|PHAR: Company Short-Term Debts|Short-Term Debt Nektar Therapeutics Inc NKTR|Company Short-Term Debts UPB|ZBIO: Short-Term Indebtedness|Company Short-Term Debt IMNM|KALV (kalvista.com) - Short-Term Debt|SEPN: Company Short-Term Debt|Short-Term Debt Volume PVLA|SVRA (Savara Corp) - Company Short-Term Debt|Short-Term Debt Volume Rigel Corp (RIGL)|Company Short-Term Debts ANAB (AnaptysBio, Inc.)|astriatx.com - Company Short-Term Debts|ENGN: Company Short-Term Debt|RAPT - Company Current Liabilities|Company Short-Term Debts JBIO|ACRS (Aclaris Therapeutics, Inc) - Short-Term Debt|KYTX - Company Short-Term Debt|Company Short-Term Loans and Borrowings tizianalifesciences.com (TLSA)|Cabaletta Bio (CABA) - Company Current Liabilities|Company Short-Term Loans and Borrowings Ventyx Biosciences Inc. (VTYX)|Company Short-Term Debts Theratechnologies Inc THTX|Company Short-Term Debt Avalo Therapeutics Inc AVTX|Company Short-Term Debts ELDN (Eledon Pharmaceuticals)|AGEN: Short-Term Debt Volume|Company Short-Term Debt CLYM|Short-Term Debt zurabio.com|ATYR - Company Current Liabilities|Company Short-Term Loans and Borrowings Adagene Corp|IMA (ImageneBio Inc) - Company Short-Term Debts|Short-Term Debt Volume STTK (shattucklabs.com)|EQ - Company Short-Term Debt|Company Short-Term Indebtedness Connect Biopharma Holdings CNTB|IMUX: Company Short-Term Debts|Atara Biotherapeutics (ATRA) - Company Current Liabilities|inflarx.de - Company Current Liabilities|x4pharma.com (XFOR) - Short-Term Debt Volume|Adicet Bio Inc. - Company Short-Term Debts|Short-Term Indebtedness CELU|INmune Bio Corp - Company Short-Term Debt|Short-Term Debt BRNS (Barinthus Biotherapeutics Corp)|Company Short-Term Debt KZR|sabbiotherapeutics.com - Short-Term Debt Volume|Company Short-Term Debt AKTX (Akari Therapeutics Plc)|ENLV: Short-Term Debt Volume|Company Short-Term Debt q32bio.com (QTTB)|GeoVax Corp (GOVX) - Current Liabilities|EDSA - Company Short-Term Debts|Company Short-Term Loans and Borrowings ibioinc.com|Company Short-Term Debts CARM|Company Short-Term Debts XTLB (XTL Biopharmaceuticals Ltd)|Company Short-Term Debt Bolt Biotherapeutics, Inc.|HCW Biologics, Inc. - Company Short-Term Loans and Borrowings|APVO: Company Short-Term Debt|AIM - Company Current Liabilities|ADTX: Company Short-Term Debts|Company Short-Term Debts GRI Bio Inc|XRTX - Company Current Liabilities|Company Short-Term Loans and Borrowings Vyome Therapeutics|REVB (Revelation Biosciences) - Company Short-Term Debts|Short-Term Debt Volume INDP (indaptusrx.com)|Scinai Immunotherapeutics Ltd. - Company Short-Term Debt|CalciMedica Inc - Company Current Liabilities|AFMD: Company Short-Term Debt|Allakos Inc. (ALLK) - Company Current Liabilities|HOOK: Company Current Liabilities|IGMS (IGM Biosciences) - Company Short-Term Debts|Company Short-Term Debt iTeos Therapeutics, Inc. (ITOS)|Company Short-Term Indebtedness Ocean Biomedical Inc|TC BioPharm (Holdings) PLC - Company Short-Term Debts|Short-Term Debt Third Harmonic Bio Inc (THRD)